By PPN News Staff
The FDA expanded the emergency use authorization for the messenger RNA COVID-19 vaccine developed by Pfizer-BioNTech to allow a booster for individuals 12 years of age and older.
The booster dose is the same dosage strength (30 mcg) as the dose approved in the primary series.
The FDA reviewed real-world data from Israel, including safety data from more than 6,300 individuals 12 through 15 years of age who received a booster dose of the vaccine at least five months following